These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28709818)

  • 1. Are Allergen Immunotherapy Dose Adjustments Needed for Local Reactions, Peaks of Season, or Gaps in Treatment?
    Epstein TE; Tankersley MS
    J Allergy Clin Immunol Pract; 2017; 5(5):1227-1233. PubMed ID: 28709818
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic reactions to immunotherapy during mountain cedar season: implications for seasonal dose adjustment.
    Wong PH; Quinn JM; Gomez RA; Webb CN
    J Allergy Clin Immunol Pract; 2017; 5(5):1438-1439.e1. PubMed ID: 28499782
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors for systemic reactions to allergen-specific subcutaneous immunotherapy.
    Iglesias-Cadarso A; Hernández-Weigand P; Reaño M; Pérez-Pimiento A; Vargas Núñez JA; de la Torre F
    J Investig Allergol Clin Immunol; 2010; 20(7):621-2. PubMed ID: 21314007
    [No Abstract]   [Full Text] [Related]  

  • 4. Local reactions from subcutaneous allergen immunotherapy.
    Coop CA
    Immunotherapy; 2013 Dec; 5(12):1339-45. PubMed ID: 24283844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half of systemic reactions to allergen immunotherapy are delayed, majority require treatment with epinephrine.
    Cook KA; Ford CM; Leyvas EA; Waalen J; White AA
    J Allergy Clin Immunol Pract; 2017; 5(5):1415-1417. PubMed ID: 28454684
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal dosing of allergen immunotherapy: efficacy, safety, long-lasting effect.
    Senna G; Crivellaro MA; Bonadonna P; Dama AR; Schiappoli M; Passalaqua
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):386-92. PubMed ID: 14768524
    [No Abstract]   [Full Text] [Related]  

  • 7. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization.
    Bird JA; Feldman M; Arneson A; Dougherty I; Brown LS; Burk CM; Kulis M; Burks W; Gill M
    J Allergy Clin Immunol Pract; 2015; 3(3):433-5.e1-3. PubMed ID: 25609341
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shooting for a faster approach to the immunotherapy target: will cluster become conventional?
    Cox LS
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):177-8. PubMed ID: 19354062
    [No Abstract]   [Full Text] [Related]  

  • 10. The LOCAL Study: Local reactions do not predict local reactions in allergen immunotherapy.
    Calabria CW; Coop CA; Tankersley MS
    J Allergy Clin Immunol; 2009 Oct; 124(4):739-44. PubMed ID: 19767075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunologic assessment of a cluster method during allergen immunotherapy refill dosing.
    Waibel KH; Owens TJ; Crisp HC; Gomez RA
    J Allergy Clin Immunol Pract; 2014; 2(6):793-4. PubMed ID: 25439374
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hyposensitization in allergic diseases?].
    Fuchs E
    Dtsch Med Wochenschr; 1988 Jun; 113(25):1025-8. PubMed ID: 3289877
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of allergen injection immunotherapy in real life.
    Borghesan F; Manzotti G
    Eur Ann Allergy Clin Immunol; 2013 Apr; 45(2):63-4. PubMed ID: 23821836
    [No Abstract]   [Full Text] [Related]  

  • 14. The safety of initiating Hymenoptera immunotherapy at 1 microg of venom extract.
    Roumana A; Pitsios C; Vartholomaios S; Kompoti E; Kontou-Fili K
    J Allergy Clin Immunol; 2009 Aug; 124(2):379-81. PubMed ID: 19560804
    [No Abstract]   [Full Text] [Related]  

  • 15. Current status of allergen immunotherapy. Shortened version of a World Health Organisation/International Union of Immunological Societies Working Group Report.
    Lancet; 1989 Feb; 1(8632):259-61. PubMed ID: 2563421
    [No Abstract]   [Full Text] [Related]  

  • 16. What should drive the choice of allergen for immunotherapy in polysensitized patients?
    Ciprandi G; Incorvaia C; Puccinelli P; Dell'Albani I; Frati F
    Ann Allergy Asthma Immunol; 2012 Aug; 109(2):148-9. PubMed ID: 22840259
    [No Abstract]   [Full Text] [Related]  

  • 17. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.
    Senti G; Graf N; Haug S; Rüedi N; von Moos S; Sonderegger T; Johansen P; Kündig TM
    J Allergy Clin Immunol; 2009 Nov; 124(5):997-1002. PubMed ID: 19733905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergen immunotherapy.
    Ewan PW
    Curr Opin Immunol; 1989 Apr; 1(4):672-8. PubMed ID: 2679719
    [No Abstract]   [Full Text] [Related]  

  • 19. The management of local reactions due to allergen immunotherapy.
    Taşkapan O
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):94. PubMed ID: 14756475
    [No Abstract]   [Full Text] [Related]  

  • 20. LAIS - Posological schedules.
    Bruno M
    Int J Immunopathol Pharmacol; 2005; 18(4 Suppl):33-4. PubMed ID: 17761105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.